Stem Med Pte. Ltd.
Quick facts
Phase 3 pipeline
- Autologous BM MSC · Regenerative Medicine
Autologous bone marrow-derived mesenchymal stem cells (BM MSCs) are harvested from the patient's own bone marrow and administered to promote tissue repair and modulate immune responses.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Stem Med Pte. Ltd.
What is Stem Med Pte. Ltd.'s pipeline?
Stem Med Pte. Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Autologous BM MSC.
Related
- Sector hub: All tracked pharma companies